diphenhydramine hydrochloride has been researched along with aprepitant in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badri, H; Smith, JA | 1 |
| Belvisi, MG; Birrell, MA; Blackhall, F; Dockry, R; Harle, A; Holt, K; Molassiotis, A; Robinson, R; Russell, P; Smith, JA; Yorke, J | 1 |
| Birring, SS; Turner, RD | 1 |
| Coveñas, R; Morell, F; Muñoz, M; Muñoz, ME | 1 |
1 review(s) available for diphenhydramine hydrochloride and aprepitant
| Article | Year |
|---|---|
Emerging targets for cough therapies; NK1 receptor antagonists.
Topics: Animals; Antitussive Agents; Aprepitant; Cough; Humans; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1 | 2019 |
1 trial(s) available for diphenhydramine hydrochloride and aprepitant
| Article | Year |
|---|---|
Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Topics: Aged; Antitussive Agents; Aprepitant; Cough; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vagus Nerve Stimulation | 2021 |
2 other study(ies) available for diphenhydramine hydrochloride and aprepitant
| Article | Year |
|---|---|
Neurokinin-1 Receptor Inhibition and Cough.
Topics: Antitussive Agents; Aprepitant; Cough; Humans; Lung Neoplasms; Receptors, Neurokinin-1 | 2021 |
Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?
Topics: Antitussive Agents; Aprepitant; Humans; Lung Neoplasms | 2022 |